Patents by Inventor Glenn Meyer

Glenn Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Controlled Release Dosage Form with Enhanced Pharmacokinetics
    Publication number: 20190070121
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
  • Controlled release dosage form
    Patent number: 10213403
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: February 26, 2019
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Composition and method for treating neurological disease
    Patent number: 10213393
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: February 26, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Composition and method for treating neurological disease
    Patent number: 10213394
    Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: February 26, 2019
    Assignee: Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság
    Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
  • Controlled release dosage form
    Patent number: 10213402
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: February 26, 2019
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Controlled release dosage form
    Patent number: 10213404
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: February 26, 2019
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Controlled release dosage form with enhanced pharmacokinetics
    Patent number: 10172800
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: January 8, 2019
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
  • Controlled Release Dosage Form
    Publication number: 20180200214
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: March 13, 2018
    Publication date: July 19, 2018
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
  • Controlled Release Dosage Form
    Publication number: 20180200215
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: March 13, 2018
    Publication date: July 19, 2018
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
  • Tool bit case
    Patent number: 9937614
    Abstract: A tool bit storage system includes a plurality of tool bits with each tool bit having a head and a drive portion. The tool bit storage system also includes a tool bit case having a bottom surface and a plurality of bit retainers extending from the bottom surface with each bit retainer supporting one of the plurality of tool bits at an oblique angle relative to the bottom surface so that the drive portion of the one of the plurality of tool bits extends generally away from the bottom surface and the head of the one of the plurality of tool bits extends generally toward the bottom surface.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: April 10, 2018
    Assignee: MILWAUKEE ELECTRIC TOOL CORPORATION
    Inventor: Glenn Meyers
  • Controlled Release Dosage Form
    Publication number: 20170354625
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: August 18, 2017
    Publication date: December 14, 2017
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
  • Triple combination release multi-layered tablet
    Patent number: 9833412
    Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: December 5, 2017
    Assignee: Osmotica Kereskedelmi es Szolgaltato KFT
    Inventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
  • Controlled Release Dosage Form
    Publication number: 20170340592
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
  • Controlled Release Dosage Form with Enhanced Pharmacokinetics
    Publication number: 20170340570
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
  • Controlled release dosage form
    Patent number: 9801841
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: October 31, 2017
    Assignee: Osmotica Kereskedelmi és Szolgáltató KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Controlled Release Dosage Form
    Publication number: 20170216236
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: April 20, 2017
    Publication date: August 3, 2017
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
  • Neutron interrogation systems using pyroelectric crystals and methods of preparation thereof
    Patent number: 9723704
    Abstract: According to one embodiment, an apparatus includes a pyroelectric crystal, a deuterated or tritiated target, an ion source, and a common support coupled to the pyroelectric crystal, the deuterated or tritiated target, and the ion source. In another embodiment, a method includes producing a voltage of negative polarity on a surface of a deuterated or tritiated target in response to a temperature change of a pyroelectric crystal, pulsing a deuterium ion source to produce a deuterium ion beam, accelerating the deuterium ion beam to the deuterated or tritiated target to produce a neutron beam, and directing the ion beam onto the deuterated or tritiated target to make neutrons using a voltage of the pyroelectric crystal and/or an HGI surrounding the pyroelectric crystal. The directionality of the neutron beam is controlled by changing the accelerating voltage of the system. Other apparatuses and methods are presented as well.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: August 1, 2017
    Assignee: Lawrence Livermore National Security, LLC
    Inventors: Vincent Tang, Glenn A. Meyer, Steven Falabella, Gary Guethlein, Brian Rusnak, Stephen Sampayan, Christopher M. Spadaccini, Li-Fang Wang, John Harris, Jeff Morse
  • Controlled release dosage form
    Patent number: 9655858
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: May 23, 2017
    Assignee: Osmotica Kereskedelmi es Szolgaltato KFT
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Controlled release dosage form
    Patent number: 9585843
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: March 7, 2017
    Assignee: Osmotica Kereskedelmi es Szoloaltato Kft
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Controlled release dosage form
    Patent number: 9579289
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 28, 2017
    Assignee: Osmotica Kereskedelmi es Szolgaltato Kft
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright